--- title: "Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm" type: "News" locale: "en" url: "https://longbridge.com/en/news/290886084.md" description: "Kuehn Law, PLLC is investigating Corcept Therapeutics (CORT) for potential breaches of fiduciary duty. The firm alleges the company failed to disclose FDA concerns regarding its drug candidate relacorilant and the risk of rejection for its New Drug Application, despite public optimism about approval. Shareholders who purchased CORT stock prior to October 31, 2024, are encouraged to contact the law firm to discuss potential legal action." datetime: "2026-06-25T22:41:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290886084.md) - [en](https://longbridge.com/en/news/290886084.md) - [zh-HK](https://longbridge.com/zh-HK/news/290886084.md) --- # Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of **Corcept Therapeutics Incorporated ()** breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company's clinical development program assessing relacorilant's effectiveness and that relacorilant's New Drug Application faced a material risk of rejection. If you currently own CORT **and purchased prior to October 31, 2024** please contact Sophia Anne Silayan by email at sophiaanne@kuehn.law or call (833) 672-0814. **Kuehn Law pays all case costs and does not charge its investor clients.** _Shareholders should contact the firm immediately as there may be limited time to enforce your rights._ **Why Your Participation Matters:** As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. _Your investment. Your voice. Your future._™ For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts: Kuehn Law, PLLC Justin Kuehn, Esq. 53 Hill Street, Suite 605 Southampton, NY 11968 justin@kuehn.law (833) 672-0814 SOURCE Kuehn Law, PLLC ### Related Stocks - [CORT.US](https://longbridge.com/en/quote/CORT.US.md) ## Related News & Research - [Dimensional Fund Advisors LP Lowers Holdings in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/294598913.md) - [27,200 Shares in Corcept Therapeutics Incorporated $CORT Purchased by OMERS ADMINISTRATION Corp](https://longbridge.com/en/news/294485103.md) - [Wolfe Research Reiterates "Underperform" Rating for Corcept Therapeutics (NASDAQ:CORT)](https://longbridge.com/en/news/293929462.md) - [Corcept (CORT) Q2 Earnings: What To Expect](https://longbridge.com/en/news/294004716.md) - [Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook](https://longbridge.com/en/news/294253972.md)